Margareth Jorvid

Margareth Jorvid graduated as a pharmacist from the University in Uppsala in 1984. She started working as a reviewer of the chemical and pharmaceutical documentation at the Department of Drugs, National Health and Welfare (today the Medical Products Agency) in Sweden.
Since 1986, Margareth has worked in the Nordic affiliate of Roussel Uclaf, Hoechst Roussel and Hoechst Marion Roussel, based in Stockholm and responsible for regulatory affairs in the Nordic area and the Baltic States. In 1998 she moved to European Regulatory affairs for Hoechst Marion Roussel (HMR) in Paris, France, responsible for the group handling HMRs marked products with staff based in Paris, Frankfurt and London. In 2000 she moved back to Sweden and worked for 2 years as a consultant at Scandinavian Regulatory Services in parallel to studying a Master of Business Administration (MBA) at the Stockholm School of Economics. Since April 2002 she is Director of Regulatory Affairs and Development at NeoPharma in Uppsala, Sweden. She lives in Uppsala with family including two children, 8 and 10 years old. Favourite hobbies are travelling, reading and figureskating (with experience as competitor, coach and judge).

Prof. Dr. Klaus Cichutek

Prof. Cichutek joined the Paul-Ehrlich-Institut in 1988 as Head of the Molecular Biology Research Group focusing on basic research in HIV/SIV pathogenesis and characterisation of acutely oncogenic retroviruses .
Since 1994 he has been Head of the Department of Medical Biotechnology. He is responsible e. g. for gene transfer medicinal products, nucleic acid vaccines and xenotransplantation. Since 1999 he is the Deputy Acting Director of the Paul-Ehrlich-Institut. Klaus Cichutek is chair of the “Commission for Somatic Gene Therapy“ of the “German Medical Association“ and of the “Committee on Gene Therapy of AIDS and Infectious Diseases” of the “European Society of Gene Therapy“ (ESGT). Furthermore, he is member of the editorial board of the journals “Gene Therapy and Regulation“ and “Current Opinion in Molecular Therapeutics“. Klaus Cichutek is author of more than 50 scientific publications in basic virology and gene therapy.

Greg Perry

Currently: Director General of the European Generic Medicines Association (EGA) since 1993 (Brussels). Other current professional activities: Editor of the Journal of Generic Medicines; Vice-President (Founding Member) of the International Generic Pharmaceutical Alliance (IGPA); Chairman and Managing Director of GPA Conferences.

Previously: Managing Director of Westminster-Europe Public Affairs (London-Brussels); EU Consultant to WWF-UK (Brussels); Senior EU Advisor JMD Associates (Brussels); EU Consultant to British Film Institute (Brussels); Parliamentary Advisor to Members of the European Parliament (Brussels); PSE Scholar European Parliament (Brussels); International Officer of the Charted Institute of Management Accountants (London); Robert Schuman Scholar European Parliament (Luxembourg); Management Trainee Leicestershire County Council (Leicester). Other previous professional activities: Temporary EC Officer Amnesty International (Brussels); Candidate for the European Parliament 1989 Elections (UK); Trade union representative NALGO (UK).

Prof. Dr. Barbara Sickmüller

Professor Dr. rer. nat. Barbara Sickmüller studied phar¬macy from 1967-1970 in Marburg. 1970/77 assistant at the Institute for Pharmaceutical Chemistry and Food Chemistry, Marburg. Licensed as pharmacist in 1972 and in 1974 doctorate (Dr. rer. nat.).

From 1977 executive at the Association of the German Pharmaceutical Industry (BPI), responsible position in the section "Drug Safety" of BPI. 1984/1985 one year in the USA. Joined DIA in the USA at that time. From August 1988 beside in charge of the section "Drug Safety", head of the department "Medical affairs" of BPI. As from February 1, 1994 she was appointed Deputy Director of this department and from January 1, 1997 as Managing Director for the Medicines and Pharmacy Division of BPI. From March 2000 appointed as Deputy Director General.

Since winter semester 1987/88 yearly lectureships in the department of Pharmacy, Uni¬versity of Marburg, on "Drug Legislation". Since January 2000 appointed honorary Professor of the University of Marburg/Lahn.

Since October 1989 Member of the German Advisory Committee on prescription of pharmaceutical products (§ 53 German Drug Law - AMG) giving recommendations for the classification of medicinal products in Germany. October 2000 appointed as Member of the Advisory Council of the German Institute for Medical Documentation and Information (Deutsches Institut für medizinische Dokumentation und Information – DIMDI)

Representative of BPI in several working groups of the European Federation of the Pharmaceutical Industries and Associations (EFPIA), i. e. Scientific, Technical and Regulatory Policy Committee (STRPC), Regulatory Affairs ad hoc Group, Pharmacovigilance ad hoc Group; former Member of the DIA Steering Committee for Europe (SCE).